(BBIO) BridgeBio Pharma - Performance 42.1% in 12m
Compare BBIO with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
9.32%
#31 in Group
Rel. Strength
87.39%
#1007 in Universe
Total Return 12m
42.06%
#31 in Group
Total Return 5y
28.04%
#33 in Group
P/E -
(?) Percentile in Group
P/E Forward -
(?) Percentile in Group
PEG -
(?) Percentile in Group
FCF Yield -6.62%
(?) Percentile in Group
12m Total Return: BBIO (42.1%) vs XBI (-5.4%)

5y Drawdown (Underwater) Chart

Top Performers in Biotechnology
Overall best picks of Peer Group Selected by proven GARP Predictive Metrics, sorted by Growth Rating
Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability |
EPS CAGR |
---|---|---|---|---|---|---|---|---|
UTHR NASDAQ United Therapeutics |
-4.25% | 15.2% | 163% | 12.1 | 10.6 | 1.43 | 81.5% | 18.5% |
HLN NYSE Haleon |
2.64% | 25.8% | 43.6% | 24.4 | 20.2 | 1.79 | 64.4% | 6.58% |
AMGN NASDAQ Amgen |
-7.54% | 5.43% | 43.3% | 38.5 | 13.8 | 0.97 | -42.0% | -25.9% |
LONN SW Lonza |
8.68% | 15.4% | 38.7% | 65.8 | 33.6 | 1.23 | 12.6% | -10.3% |
BIM PA Biomerieux |
2.77% | 21.2% | 8.84% | 31 | 24.2 | 1.45 | -58.7% | -25.1% |
KMDA NASDAQ Kamada |
-1.94% | 25.9% | -9.16% | 26.6 | 24 | 0.96 | 80.4% | 43% |
ERF PA Eurofins Scientific SE |
15.4% | 0.42% | 17.2% | 26.6 | 13.6 | 0.56 | -67.4% | -17.7% |
BMRN NASDAQ Biomarin Pharmaceutical |
-7.7% | -24.7% | -30.6% | 28.6 | 15.9 | 0.43 | 67.5% | 59.7% |
Performance Comparison: BBIO vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for BBIO
Total Return (including Dividends) | BBIO | XBI | S&P 500 |
---|---|---|---|
1 Month | 16.29% | 5.55% | -0.45% |
3 Months | 23.75% | -9.75% | -6.29% |
12 Months | 42.06% | -5.39% | 13.04% |
5 Years | 28.04% | -13.20% | 111.82% |
Trend Score (consistency of price movement) | BBIO | XBI | S&P 500 |
1 Month | 76.4% | 70% | 47.5% |
3 Months | 30.9% | -88.1% | -87.3% |
12 Months | 56.6% | -44.4% | 54.3% |
5 Years | -31.1% | -53.6% | 84.2% |
Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
1 Month | #61 | 10.2% | 16.8% |
3 Month | #16 | 37.1% | 32.1% |
12 Month | #30 | 50.2% | 25.7% |
5 Years | #33 | 47.5% | -39.6% |
FAQs
Does BBIO BridgeBio Pharma outperforms the market?
Yes,
over the last 12 months BBIO made 42.06%, while its related Sector, the SPDR S&P Biotech (XBI) made -5.39%.
Over the last 3 months BBIO made 23.75%, while XBI made -9.75%.
Over the last 3 months BBIO made 23.75%, while XBI made -9.75%.
Performance Comparison BBIO vs Indeces and Sectors
BBIO vs. Indices BBIO is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | 4.64% | 16.7% | 52.3% | 29.0% |
US NASDAQ 100 | QQQ | 3.72% | 14.4% | 51.6% | 27.1% |
US Dow Jones Industrial 30 | DIA | 5.18% | 19.1% | 53.1% | 32.8% |
German DAX 40 | DAX | 5.0% | 16.5% | 34.2% | 17.1% |
Shanghai Shenzhen CSI 300 | CSI 300 | 8.29% | 19.5% | 56.0% | 37.1% |
Hongkong Hang Seng | HSI | 5.04% | 17.8% | 51.8% | 29.1% |
India NIFTY 50 | INDA | 7.16% | 11.4% | 52.4% | 39.2% |
Brasil Bovespa | EWZ | 6.27% | 13.5% | 46.6% | 48.8% |
BBIO vs. Sectors BBIO is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | 4.49% | 16.9% | 46.3% | 18.6% |
Consumer Discretionary | XLY | 4.61% | 16.9% | 51.1% | 27.4% |
Consumer Staples | XLP | 6.70% | 17.1% | 48.2% | 31.1% |
Energy | XLE | 8.90% | 30.3% | 57.4% | 51.4% |
Financial | XLF | 5.75% | 18.3% | 45.4% | 19.4% |
Health Care | XLV | 7.34% | 21.0% | 57.5% | 43.3% |
Industrial | XLI | 4.32% | 16.0% | 51.3% | 31.4% |
Materials | XLB | 6.45% | 19.5% | 60.1% | 46.5% |
Real Estate | XLRE | 4.75% | 17.4% | 52.1% | 23.7% |
Technology | XLK | 3.08% | 13.9% | 55.2% | 31.6% |
Utilities | XLU | 5.92% | 16.2% | 47.9% | 21.3% |
Aerospace & Defense | XAR | 3.61% | 9.31% | 38.4% | 14.6% |
Biotech | XBI | 4.80% | 10.7% | 67.6% | 47.5% |
Homebuilder | XHB | 5.91% | 18.4% | 67.3% | 48.2% |
Retail | XRT | 5.88% | 17.5% | 58.3% | 43.6% |